John Anson brings to OGT a wide experience of product development for the life science market, having led teams responsible for the launch of several industry-leading products
Oxford Gene Technology (OGT) announces the appointment of John Anson as research and development director.
Anson joins OGT after 16 years at Amersham Biosciences/GE Healthcare where he held positions as head of product development, lead discovery, Cardiff; vice president for pharmacogenomics; vice president for business development, and programme manager.
Anson brings to OGT a wide experience of product development for the life science market, having led teams responsible for the launch of several industry-leading products, including the In Cell analyser for automated cell-based assays and Leadseeker for in vitro drug screening.
Prior to Amersham Biosciences, Anson carried out post doctorate research at PHLS Centre for Applied Microbiology and Research, Porton Down, and holds a PhD in bacterial genetics from Cranfield University and a BSc (Hons) in microbiology from the University of Kent.
"I am looking forward to joining OGT and working with its scientists to develop products and services for commercialisation into the life science and molecular medicine markets," he said.
Mike Evans, OGT's chief executive, said: "I am delighted to welcome John to OGT.
"With his track record and experience in research, product development and management of collaborations, he will make a major contribution to OGT's development of products and services for the life science and molecular medicine markets".
Oxford Gene Technology (OGT) is a privately owned company founded in 1995 by Professor Sir Edwin Southern.
The mission of the company is to develop advanced molecular tools for biologists and to make them widely available through licensing and service activities.
The key business areas of OGT include licensing, which has successfully provided access for a number of companies to OGT's fundamental intellectual property particularly in the area of microarrays; a services business which provides a flexible and cost-effective, customised DNA microarray service covering a range of applications and offers specialist support to assist customers with every aspect of their research; Tridend, which is developing 'mass tags' to enhance the amount of information that researchers can generate from mass spectrometry experiments in proteomics and genomics; Oxamer, which is generating novel array formats based on electrochemical deposition methods for use in life science and diagnostics.
OGT's intellectual property covers four general areas that are relevant to the biological sciences; these incorporate microarrays, genomics, proteomics and electrochemistry.
